RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced that it has retained leading clinical research organization, Accerise Inc, with offices in Tokyo and Osaka, to lead the planning and preparations for clinical research studies of RepliCel's skin rejuvenation and tendon regeneration cell therapy products in Japan.
Both cell therapies have been the subject of successful phase 1 studies in Germany and Canada. The next-phase clinical research studies in Japan will be conducted under that country's Act for Safety of Regenerative Medicine (ASRM) and, upon successfully meeting its endpoints, could lead to a commercial launch of the products in Japan.
Read more at BioSpace >>